Diagnostic role of fluorodeoxyglucose positron emission tomography‑computed tomography in prostate cancer

Liu,Yiyan

doi:10.3892/ol.2014.1997

Diagnostic role of fluorodeoxyglucose positron emission tomography‑computed tomography in prostate cancer

Authors:
- Yiyan Liu
View Affiliations

Affiliations: Nuclear Medicine Service, Department of Radiology, New Jersey Medical School, Newark, NJ 07103, USA
Published online on: March 24, 2014 https://doi.org/10.3892/ol.2014.1997
Pages: 2013-2018

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of fluorine‑18 fluorodeoxyglucose (FDG) positron emission tomography (PET)‑computed tomography (CT) in prostate cancer remains controversial due to a limited number of previous clinical investigations. The aim of the present retrospective study was to assess the diagnostic value of FDG PET‑CT in prostate cancer, with an emphasis on the detection of metastatic disease. Twenty‑five relevant cases of patients with newly diagnosed prostate cancer, referred for staging, or with a history of prostate cancer or recent prostate specific antigen (PSA) relapse, referred for the detection of metastatic disease, were included in the present study. None of the patients had known imaging or pathological evidence of metastatic disease prior to FDG PET‑CT, however, the PSA levels had been recorded in all patients in the two months prior to FDG PET‑CT imaging. Verification of the FDG PET‑CT observations was made by biopsy, regional diagnostic CT and/or whole‑body bone scintigraphy. The sensitivity of FDG PET‑CT in identifying untreated primary lesions was only 33% (3/9). However, FDG PET‑CT detected metastatic disease in six of the nine patients who underwent initial staging. Out of 16 patients with previous treatments and recent PSA relapse, FDG PET‑CT successfully identified metastatic diseases in 12 and tumor recurrence within the prostatic fossa of two patients. The difference in the PSA levels was identified to be statistically significant between the FDG PET‑CT‑positive and ‑negative subgroups of the 16 restaging patients. The results indicated that FDG PET‑CT is not useful for the diagnosis of prostate cancer, but may aid with the detection of metastatic disease in appropriately selected patients.

View Figures

View References

1	Ravizzini G, Turkbey B, Kurdziel K and Choyke PL: New horizons in prostate cancer imaging. Eur J Radiol. 70:212–226. 2009. View Article : Google Scholar : PubMed/NCBI
2	Powels T, Murray I, Brock C, Oliver T and Avril N: Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 51:1520–1521. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lawrentschuk N, Davis ID, Bolton DM and Scott AM: Positron emission tomography and molecular imaging of the prostate: an update. BJU Int. 97:923–931. 2006. View Article : Google Scholar : PubMed/NCBI
4	Effert PJ, Bares R, Handt S, Wolff JM, Büll U and Jakse G: Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 155:994–998. 1996. View Article : Google Scholar
5	Kapoor V, McCook BM and Torok FS: An introduction to PET-CT imaging. Radiographics. 24:523–543. 2004. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Ghesani NV and Zuckier LS: Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 40:294–315. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hofer C, Laubenbacher C, Block T, Breul J, Hartung R and Schwaiger M: Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 36:31–35. 1999. View Article : Google Scholar
8	Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y and Okada K: The increased accumulation of [18F]-fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 29:623–629. 1999.
9	Liu IJ, Zafar MB, Lai YH, Segall GM and Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 57:108–111. 2001. View Article : Google Scholar : PubMed/NCBI
10	Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, Shizukuishi K, Tateishi U, Kubota Y and Inoue T: The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 25:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
11	Candler JD, Williams ED, Slavin JL, Best JD and Rogers S: Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 97:2035–2042. 2003. View Article : Google Scholar : PubMed/NCBI
12	Singh G, Lakkis CL, Laucirica R and Epner DE: Regulation of prostate cell division by glucose. J Cell Physiol. 180:431–438. 1999. View Article : Google Scholar : PubMed/NCBI
13	Liu Y, Zuckier LS and Ghesani NV: Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 30:369–374. 2010.PubMed/NCBI
14	Heicappell R, Müller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Müller-Gärtner H and Ackermann R: Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol. 36:582–587. 1999.
15	Chang CH, Wu HC, Tsai JJ, Shen YY, Changlai SP and Kao A: Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 70:311–315. 2003. View Article : Google Scholar
16	Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher HI and Larson SM: 2-[18F]fluororo-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostatic-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 11:4761–4769. 2005.
17	Effert P, Beniers AJ, Tamimi Y, Hardt S and Jakse G: Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 24:3057–3063. 2004.PubMed/NCBI
18	Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, Sato H, Kondo Y, Tsuchiya S and Kumita S: Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 26:138–145. 2012. View Article : Google Scholar : PubMed/NCBI
19	Jadvar H: Prostate cancer. Methods Mol Biol. 727:265–290. 2011. View Article : Google Scholar
20	Bouchelouche K, Tagawa ST, Glodsmith SJ, Turkbey B, Capala J and Choyke P: PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med. 41:29–44. 2011. View Article : Google Scholar : PubMed/NCBI